Bicyclo Ring System Patents (Class 514/657)
  • Patent number: 11433102
    Abstract: The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes or a sterile fecal filtrate for treating Parkinson's disease and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: September 6, 2022
    Assignee: Finch Therapeutics Holdings LLC
    Inventor: Thomas J. Borody
  • Patent number: 10829427
    Abstract: Provided herein are naphthoquinones compounds such as those with a hydrogen bond donating group of the formula (I): wherein: R1, R2, R3, R4, R5, and n are as defined herein. Also provided herein are pharmaceutical composition of the present compounds and methods of treatment using the compounds including their use in the treatment of cancer.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 10, 2020
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Jinming Gao, Yuliang Liu, Qi Wei, Xinpeng Ma, Gang Huang
  • Patent number: 10646457
    Abstract: A composition for the treatment of emesis comprising 8-hydroxy-2-(dipropylamino)tetralin in which the ratio of the S enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin to the R enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin is between 2:1 and 10:1, and a method of treating or preventing emesis with such a composition.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: May 12, 2020
    Assignee: REPURPOSED THERAPEUTICS, INC
    Inventors: David Helton, James Lucot
  • Patent number: 10435351
    Abstract: A convenient method for converting oximes into enamides is disclosed. The process produces enamides without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: October 8, 2019
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Charles P. Vandenbossche, John R. Snoonian
  • Patent number: 10406123
    Abstract: Methods and compositions utilizing 2-aminoindan derivatives collectively represented by Formula I as described and defined in the specification for regulating binge behavior, particularly binge drinking, are disclosed.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: September 10, 2019
    Inventor: Ezekiel Golan
  • Patent number: 10206889
    Abstract: A composition for the treatment of emesis comprising 8-hydroxy-2-(dipropylamino)tetralin in which the ratio of the S enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin to the R enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin is between 2:1 and 10:1, and a method of treating or preventing emesis with such a composition.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: February 19, 2019
    Assignee: REPURPOSED THERAPEUTICS, INC.
    Inventors: David Helton, James Lucot
  • Patent number: 10137096
    Abstract: Methods and compositions utilizing 2-aminoindan derivatives collectively represented by Formula I as described and defined in the specification for regulating binge behavior, particularly binge drinking, are disclosed.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: November 27, 2018
    Inventor: Ezekiel Golan
  • Patent number: 10011559
    Abstract: This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: July 3, 2018
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Hang Zhao, Stefan G. Koenig, Charles P. Vandenbossche, Surendra Singh, Harold Scott Wilkinson, Roger P. Bakale
  • Patent number: 9918949
    Abstract: A method of treating or preventing emesis through the administration of an effective dosage of a 2-(amino)tetralin compound in which one of the S or R enantiomers of the 2-(amino) tetralin compound is present in the composition in excess of the other enantiomer, and compositions comprising such a 2-(amino)tetralin compound in which the ratio of the S and R enantiomers is at least 2:1.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: March 20, 2018
    Assignee: Repurposed Therapeutics, Inc.
    Inventors: David Helton, James Lucot
  • Patent number: 9493434
    Abstract: The present invention relates to new indene derivatives of formula (I) having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: November 15, 2016
    Assignee: LABORATORIOS DEL DR. ESTEVE S.A.
    Inventors: Maria de las Ermitas Alcalde-Pais, Carmen Almansa-Rosales, José´Luis Diaz Fernández, María de les Neus Mesquida-Estevez, Laura Paloma-Romeu
  • Publication number: 20150148359
    Abstract: Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1 inhibitor as a cytotoxic inhibitor of undifferentiated cells.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 28, 2015
    Inventors: Uri Ben-David, Nissim Benvenisty, Payal Arora, Qing-Fen Gan, Ralph J. Garippa
  • Publication number: 20150141384
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing neurological degenerative disorders, may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of Alzheimer's disease, Lewy body disease, Huntington's disease, Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.
    Type: Application
    Filed: June 23, 2013
    Publication date: May 21, 2015
    Inventor: Mahesh KANDULA
  • Patent number: 9017723
    Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix of the propynylaminoindan in a pressure sensitive adhesive comprising a carboxylated polymer. In some instances, the matrix further includes a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: April 28, 2015
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Jianye Wen, Richard Hamlin
  • Publication number: 20150110718
    Abstract: The present invention is directed to methods and assays for identifying subjects participating in clinical trials that may exhibit a placebo response and identifying treatments for subjects with varying degrees of placebo responses. In one aspect, a method of selecting subjects to participate in a clinical trial is disclosed. In another aspect, methods for treating a subject and determining a treatment dosage are disclosed. In an exemplary embodiment, a method for determining a response to a treatment of a subject having, suspected of having, or at risk for developing a disorder, such as cardiovascular disorder, irritable bowel syndrome, diabetes, autoimmune disorders, inflammation, neurological disorders, chronic pain, cancer, cancer treatments, allergies, depression, migraines, addiction, obesity, and other disorders, syndromes, or diseases, is disclosed.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 23, 2015
    Inventors: Gunther Winkler, Kathryn T. Hall, Ted J. Kaptchuk
  • Publication number: 20150080438
    Abstract: The invention relates to selective oestrogen receptor modulators (SERMs) and to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of bleeding disorders, osteoporosis, endometriosis, myomata, hormone-dependent tumours, for hormone replacement therapy and for contraception.
    Type: Application
    Filed: December 4, 2012
    Publication date: March 19, 2015
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Tim Wintermantel, Carsten Moeller, Ulrich Bothe, Reinhard Nubbemeyer, Ludwig Zorn, Antonius Ter Laak, Rolf Bohlmann, Lars Wortmann
  • Patent number: 8980321
    Abstract: A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: March 17, 2015
    Assignee: Bend Research, Inc.
    Inventors: William J. Curatolo, Ravi M. Shanker, Walter C. Babcock, Dwayne T. Friesen, James A. S. Nightingale, Douglas A. Lorenz
  • Publication number: 20150073177
    Abstract: Methods are provided to inhibit proliferation of Trypanosoma cruzi with imido-substituted 1,4-naphthoquinones, including novel compounds. Administering an imido-substituted 1,4-naphthoquinone can be used to provide prophylaxis or treatment to a patient in need of treatment against Chagas disease.
    Type: Application
    Filed: July 27, 2012
    Publication date: March 12, 2015
    Applicant: HOWARD UNIVERRSITY
    Inventors: Oladapo Bakare, Clarence M. Lee, Yakini Brandy, Mozna Husein Khraiwesh
  • Publication number: 20150064250
    Abstract: The invention provides a tamper-resistant dosage form including a therapeutic agent-substrate complex embedded in a thermo-formable matrix; such that the complex includes at least one therapeutic agent bound to at least one substrate to form the therapeutic agent-substrate complex. The at least one substrate is being selected from the group consisting of a polyelectrolyte, an organic counter-ion, a pharmacologically inert organic component of a prodrug, an inclusion compound and an inorganic adsorbent; and the thermo-formable matrix includes one or more thermoplastic polymers and optionally at least one pharmaceutical additive.
    Type: Application
    Filed: January 17, 2014
    Publication date: March 5, 2015
    Applicant: ExxPharma Therapeutics LLC
    Inventors: Isaac Ghebre-Sellassie, Hibreniguss Terefe
  • Patent number: 8962677
    Abstract: Disclosed are methods of enhancing cognitive impairment in a patient wherein the cognitive impairment is due to ADDL neurotoxicity. The methods employ non-peptidic compounds having a molecular weight of less than 1000 and which can antagonize against formation of neurotoxic ADDLs from A?1-42 monomers.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: February 24, 2015
    Assignee: Acumen Pharmaceuticals, Inc.
    Inventors: Grant A. Krafft, Todd Pray, William F. Goure
  • Publication number: 20150045445
    Abstract: The subject invention provides a pharmaceutical composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of 3-keto-N-propargyl-1-aminoindan or a salt thereof.
    Type: Application
    Filed: October 23, 2014
    Publication date: February 12, 2015
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Anton Frenkel, Ramy Lidor-Hadas, Eliezer Bahar
  • Patent number: 8946482
    Abstract: The present invention relates to salts of rasagiline and pharmaceutical preparations thereof. The invention further provides a method of preparing the salts of rasagiline.
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: February 3, 2015
    Assignee: Ratiopharm GmbH
    Inventors: Thomas Thyrann, Christian Janssen, Ramesh Matioram Gidwani
  • Publication number: 20150031768
    Abstract: Methods of halogenating a carbon containing compound having an sp3 C—H bond are provided. Methods of fluorinating a carbon containing compound comprising halogenation with Cl or Br followed by nucleophilic substitution with F are provided. Methods of direct oxidative C—H fluorination of a carbon containing compound having an sp3 C—H bond are provided. The halogenated products of the methods are provided.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 29, 2015
    Inventors: John T. Groves, Wei Liu, Xiongyi Huang
  • Publication number: 20150030539
    Abstract: This invention relates to novel compounds suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).
    Type: Application
    Filed: July 21, 2014
    Publication date: January 29, 2015
    Applicant: PIRAMAL IMAGING SA
    Inventors: Lutz LEHMANN, Andrea THIELE, Tobias HEINRICH, Thomas BRUMBY, Christer HALLDIN, Balazs GULYAS, Sangram NAG
  • Publication number: 20150031774
    Abstract: This invention provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, a mixture of a disintegrant, a flow agent and particles having a non-filamentous microstructure of at least two sugar alcohols, a supplemental sugar alcohol, a supplemental flow agent, and a supplemental disintegrant. This invention further provides a method of treating a subject afflicted with Parkinson's disease comprising administering to the subject a therapeutically effective amount of the solid pharmaceutical composition, thereby treating the subject. Finally, this invention provides a process of making such solid pharmaceutical compositions.
    Type: Application
    Filed: August 13, 2014
    Publication date: January 29, 2015
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Shulamit Patashnik, Daniella Licht, Adrian Gilbert
  • Publication number: 20150005388
    Abstract: A method of treating or preventing emesis through the administration of an effective dosage of a 2-(amino)tetralin compound in which one of the S or R enantiomers of the 2-(amino) tetralin compound is present in the composition in excess of the other enantiomer, and compositions comprising such a 2-(amino)tetralin compound in which the ratio of the S and R enantiomers is at least 2:1.
    Type: Application
    Filed: July 30, 2014
    Publication date: January 1, 2015
    Inventors: David Helton, James Lucot
  • Publication number: 20140364506
    Abstract: The subject invention provides deuterated rasagiline, its salts and uses.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 11, 2014
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Elizer Bahar, Anton Frenkel, Victor Piryatinsky
  • Publication number: 20140336187
    Abstract: Methods are provided to inhibit proliferation of Leishmania parasites, and in particular Leshmania donovani with imido-substituted 1,4-naphthoquinones, including novel compounds. Administering an imido-substituted 1,4-naphthoquinone can used to provide prophylaxis or treatment to a patient in need of treatment against leishmaniasis disease.
    Type: Application
    Filed: November 16, 2012
    Publication date: November 13, 2014
    Inventors: Oladapo Bakare, Clarence M. Lee, Yakini Brandy, Cheu Manka
  • Publication number: 20140322325
    Abstract: A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.
    Type: Application
    Filed: July 14, 2014
    Publication date: October 30, 2014
    Applicant: Bend Research, Inc.
    Inventors: William J. Curatolo, Ravi M. Shanker, Walter C. Babcock, Dwayne T. Friesen, James A. S. Nightingale, Douglas A. Lorenz
  • Publication number: 20140323581
    Abstract: The invention is directed to methods to identify predisposition or risk to develop Parkinson's disease, methods to identify agents which have therapeutic effect on Parkinson's disease, and methods to determine the therapeutic effect of an agent in a subject suffering from Parkinson's disease, and to kits and reagents for carrying out the methods of the invention.
    Type: Application
    Filed: December 5, 2012
    Publication date: October 30, 2014
    Inventors: Asa Abeliovich, Hervé Rhinn
  • Patent number: 8859624
    Abstract: The present invention provides a stable composition of rasagiline comprising an effective dosage of rasagiline or its pharmaceutically acceptable salts and an antioxidant used as a stabilizer. The dosage forms of the composition are pharmaceutically common transdermal-drug delivery dosage form and mucoadhesive delivery dosage form, such as patch, gel, ointment, cream, cataplasm, film, spray and solution, etc. The composition can be used to prevent or treat mental disorders.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: October 14, 2014
    Assignee: Chongqing Pharmaceutical Research Institute Co., Ltd.
    Inventors: Jialiang Lin, Jie Deng, Hao Chen, Tao Zhang
  • Publication number: 20140271527
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a cleavable moiety.
    Type: Application
    Filed: November 1, 2012
    Publication date: September 18, 2014
    Applicant: Serina Therapeutics, Inc.
    Inventors: Randall Moreadith, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas, Michael David Bentley
  • Publication number: 20140274929
    Abstract: The present invention is directed to a crosslinked or non-crosslinked polymer particle, wherein the crosslinked polymer particle comprises a copolymer of poly(alkylene glycol-graft-acrylate) that is crosslinked by at least one hydrolysable monomer or crosslinking agent. The present invention is also directed to a polymer particle comprising a crosslinked polymer particle that is a product of starting materials comprising (a) a hydrophilic monomer, (b) a hydrophobic monomer, and (c) a hydrolysable crosslinking agent (the crosslinking agent may be absent in the case of non-crosslinked particles). The present invention is still further directed to a polymer particle comprising a crosslinked copolymer, where the crosslinked copolymer includes structures represented by Formulas (I), (II), and (III), as defined in the specification. Other embodiments of the present invention also include methods of manufacturing polymer particles.
    Type: Application
    Filed: May 30, 2014
    Publication date: September 18, 2014
    Applicant: HOWARD UNIVERSITY
    Inventors: Emmanuel Oyekanmi Akala, Oluyomi Modupe Okunola
  • Patent number: 8835503
    Abstract: A pharmaceutical composition, comprising a GluR2-lacking AMPAR antagonist as an active ingredient, is effective for preventing or treating mental diseases selected from the group consisting of posttraumatic stress disorder (PTSD), drug addiction, and phobia.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: September 16, 2014
    Assignee: SNU R&DB Foundation
    Inventors: Sukwoo Choi, Sukwon Lee, Jeongyeon Kim, Beomjong Song, Ingie Hong, Sungmo Park, Jihye Kim, Junuk Lee, Bobae An, Kisoon Shin, Kyungjoon Park
  • Patent number: 8822540
    Abstract: A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism, including, for example, oculocutaneous albinism types OCA1a and OCA1b, as well as ocular albinism type 1, resulting from mutations in the GPR143 gene, as well as the OCA2, OCA3 or OCA4 genes, by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound (2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione), also known as NTBC for a sufficient period of time. The administration of NTBC is believed to increase the amount of pigmentation in the subject and alleviate certain symptoms caused by lack of pigmentation in the eye tissues. Also described are methods of use of NTBC for increasing the pigmentation of a subject for cosmetic purposes, by administering to the subject a therapeutically effective amount of NTBC.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: September 2, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Brian P. Brooks, William A. Gahl
  • Publication number: 20140243418
    Abstract: A method for modifying Parkinson's disease by periodically administering a pharmaceutical composition comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt of rasagiline to the patient, thereby modifying the disease. The method includes reducing the rate of progression; delaying the need for symptomatic anti-Parkinsonian therapy; reducing the risk of a Parkinson's disease patient requiring symptomatic anti-Parkinsonian therapy; and reducing the functional decline.
    Type: Application
    Filed: November 27, 2013
    Publication date: August 28, 2014
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Ruth Levy, Eli Eyal, Tamar Goren, Sheila Oren, Naim Sayag, Yonatan Weiss, Miri Ben-Ami
  • Publication number: 20140213627
    Abstract: The present invention provides pharmaceutical compositions comprising substituted 1,4 naphthoquinones that are effective in preventing oligomerization of beta amyloid and subsequent pathologies associated with amyloid fibrils. These compositions are useful for the treatment of disease involving amyloidogenesis including neurodegenerative diseases such as Alzheimer's Disease or senile dementia. Particularly effective compositions comprise 1,4 naphthoquinones substituted with an amino acid residue selected from a heterocyclic or aromatic amino acid.
    Type: Application
    Filed: January 30, 2014
    Publication date: July 31, 2014
    Applicant: RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Roni SCHERZER, Ehud GAZIT, Daniel SEGAL
  • Publication number: 20140194510
    Abstract: The subject invention provides a solid dispersion of rasagiline citrate, a composition and a process for the manufacture thereof.
    Type: Application
    Filed: March 10, 2014
    Publication date: July 10, 2014
    Applicant: Teva Pharmaceutical Industries Ltd.
    Inventors: Keith Lorimer, David Engers
  • Publication number: 20140186422
    Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
    Type: Application
    Filed: October 25, 2013
    Publication date: July 3, 2014
    Applicant: TEIKOKU PHARMA USA, INC.
    Inventors: Richard D. Hamlin, Amit Jain, Jianye Wen
  • Publication number: 20140170208
    Abstract: A method for preparing a transdermal patch comprising a substrate layer is provided, the method comprising the steps of contacting an active pharmaceutical ingredient with a retaining means to provide a composition, applying the composition obtained in step (a) to a carrier material to form a substrate layer of the transdermal patch, wherein the retaining means remain within the final transdermal patch.
    Type: Application
    Filed: February 21, 2014
    Publication date: June 19, 2014
    Applicant: LABTEC GMBH
    Inventors: Sebastian BRAUN, Armin BREITENBACH, Ulrich BECKER
  • Publication number: 20140163115
    Abstract: A novel pathogenesis underlying certain types of seizures and migraines is disclosed and the validated set of premises presented enable the deductive conclusion to be made that drugs that reduce the amount of calcium ions (Ca++) released from bone reduce seizure and migraine risk. The premises validated as true in the specifications include: 1) Known seizure and migraine triggers increase osteoclast mediated release of Ca++ from bone. 2) Increased Ca++ released from bone increases seizure and migraine risk by a) depolarization of nerve membranes, b) enhanced calcium channel mediated neurotransmitter release and increases muscle contractility by c) enhanced neurotransmitter release at the neuromuscular junction and d) enhanced removal of the tropomyosin block between actin and myosin. 3) Conversely, reducing Ca++ released from bone reduces seizure and migraine risk. 4) Cinacalcet reduces Ca++ released from bone. Therefore, cinacalcet reduces migraine risk.
    Type: Application
    Filed: December 12, 2012
    Publication date: June 12, 2014
    Inventors: Mark Zamoyski, Justin John Zamoyski
  • Patent number: 8748419
    Abstract: Provided are methods of treating obesity and effecting desired weight loss or preventing undesired weight gain by administration of a preferential muscarinic acetylcholine receptor M1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist. The preferential muscarinic acetylcholine receptor M1 antagonist, optionally can be administered with an anti-obesity agent, for example, an anorexiant. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M1 antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: June 10, 2014
    Assignee: Theracos, Inc.
    Inventors: Brian Seed, Jordan Mechanic
  • Publication number: 20140155369
    Abstract: An agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that activates a serotonin 5-HT2C receptor, an agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that stimulates an androgen binding site, and a method of screening for a drug for the prophylaxis or treatment of abdominal pressure incontinence, which includes electrostimulating the abdominal muscles or a nerve controlling them of an animal to increase the abdominal pressure, and measuring the leak point pressure at that time.
    Type: Application
    Filed: January 16, 2014
    Publication date: June 5, 2014
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Izumi KAMO, Tadatoshi HASHIMOTO
  • Patent number: 8741962
    Abstract: The present invention relates to an improved process for the preparation of Rasagiline or pharmaceutically acceptable salts thereof. The present invention also relates to Rasagiline salts, polymorphs thereof and process for preparation thereof.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: June 3, 2014
    Assignee: USV Limited
    Inventors: Dhananjay Govind Sathe, Subhash Vishwanath Damle, Kamlesh Digambar Sawant, Parag Sukumar Gatne, Tushar Anil Naik
  • Publication number: 20140128474
    Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 8, 2014
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Thomas JERUSSI, Qun Kevin FANG, Mark G. CURRIE
  • Publication number: 20140127281
    Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
    Type: Application
    Filed: October 25, 2013
    Publication date: May 8, 2014
    Inventors: Richard D. Hamlin, Amit Jain, Jianye Wen
  • Publication number: 20140121187
    Abstract: Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, flu, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.
    Type: Application
    Filed: June 18, 2012
    Publication date: May 1, 2014
    Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Young Sik Jung, Chong Kgo Lee, Ihl Young Choi, Hae Soo Kim, Pil Ho Kim, Soo Bong Han, Johan Neyts, Hendrik Jan Thibaut
  • Publication number: 20140121284
    Abstract: Provided is a stable pharmaceutical composition having as an active ingredient a therapeutically effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof, an absorption modulator, and a diluent, wherein the absorption modulator is glycerin, and the diluent is anhydrous dibasic calcium phosphate (CaHPO4) or microcrystalline cellulose. The stable pharmaceutical composition in accordance with the present invention provides extremely low amount of R(+)-N-propargyl-1-aminoindan and could significantly reduce cost. Moreover, the anhydrous dibasic calcium phosphate (CaHPO4) used as the diluent could enhance fluidity and improve ingredients uniformity in powder molding process. The glycerin used as the absorption modulator could increase the absorption of active ingredient such as R(+)-N-propargyl-1-aminoindan.
    Type: Application
    Filed: October 26, 2012
    Publication date: May 1, 2014
    Applicant: Standard Chem. & Pharm. Co., Ltd.
    Inventors: Fang-Hsuing Hsiao, Chia-Sheng Cheng
  • Publication number: 20140057990
    Abstract: This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure.
    Type: Application
    Filed: August 1, 2013
    Publication date: February 27, 2014
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Hang Zhao, Stefan G. Koenig, Charles P. Vandenbossche, Surendra Singh, Harold Scott Wilkinson, Roger P. Bakale
  • Publication number: 20140051768
    Abstract: The invention relates to a medicament containing (S)-2-N-propylamino-5-hydroxytetralin, the salts or prodrugs thereof. As a D3 agonist, (S)-2-N-propylamino-5-hydroxytetralin is suitable particularly for the treatment of dopa-sensitive movement disorders.
    Type: Application
    Filed: October 25, 2013
    Publication date: February 20, 2014
    Applicant: UCB Pharma GmbH
    Inventors: Dieter Scheller, Klaus Hansen
  • Publication number: 20140051767
    Abstract: This application provides a method of preferentially inhibiting monoamine oxidase A (MAOA) in the brain of a subject relative to in the intestine of the subject comprising parenterally administering to the subject a controlled release formulation comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 16, 2013
    Publication date: February 20, 2014
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Cheryl Fitzer-Attas, Rom E. Eliaz, Eran Blaugrund, Aviva Gross, Adi Mayk